RxDoctor Payments Data

Mike Choi, MD

Family Medicine · Vestal, NYNPI 1588764484

Payments from drug & device makers

$6,457in general payments, 2019–2025

Across 374 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • AbbVie$1K
  • Pfizer$967
  • AstraZeneca$503
  • Exact Sciences$331
  • plus $480 from 9 others

What the payments were for

  • Food & beverage$6,457100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,457 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$114,658
Medicare patients
510
Services billed
2,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$105,637
JardianceEmpagliflozin82$94,463
JanuviaSitagliptin Phosphate40$52,349
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$46,797
Breo ElliptaFluticasone/Vilanterol44$29,278
FarxigaDapagliflozin Propanediol24$26,812
OzempicSemaglutide20$26,600
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$25,268
XareltoRivaroxaban19$25,251
GlyxambiEmpagliflozin/Linagliptin20$21,923
LinzessLinaclotide25$21,456
EntrestoSacubitril/Valsartan28$19,877
SymbicortBudesonide/Formoterol Fumarate29$8,513
Arnuity ElliptaFluticasone Furoate15$7,294
ArexvyRsvpref3 Antigen/As01e/Pf22$6,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat$56$121,843113 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Arexvy$1,306$121,076191 claims
PfizerEliquis$967$105,637108 claims
MerckJanuvia$73$52,34940 claims
AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere$503$40,84966 claims
Novo NordiskOzempic$1,714$26,60020 claims
Johnson & JohnsonXarelto$22$25,25119 claims
AbbVieLinzess, Synthroid$1,156$23,02454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Vestal

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →